The Experts below are selected from a list of 1213566 Experts worldwide ranked by ideXlab platform
Eran Goldin - One of the best experts on this subject based on the ideXlab platform.
-
topical capsaicin a novel and Effective Treatment for idiopathic intractable pruritus ani a randomised placebo controlled crossover study
Gut, 2003Co-Authors: Joseph Lysy, D Keret, Yardena Israelit, Avigail Shmueli, M Sistieryittah, N Straussliviatan, Victoria Mindrul, Eran GoldinAbstract:Purpose: Pruritus ani is a common and embarrassing proctological condition which can be very difficult to treat. We report the results of a double blind placebo controlled study of Treatment with capsaicin. Methods: Firstly, a pilot open study was carried out on five patients to establish which of two doses was the most acceptable by comparing Effectiveness and side effects. Secondly, a double blind, placebo controlled, crossover study of topical capsaicin was performed. This study involved two four week Treatment phases separated by a one week washout phase. Forty four patients were randomised to receive locally either active capsaicin (0.006%) or placebo (menthol 1%) ointment over a four week period (22 patients per group). After four weeks of Treatment and a one week washout period, the placebo group began to receive capsaicin while the treated group received placebo (menthol 1%) for another four weeks. At the end of the controlled study, responders from both groups continued with capsaicin Treatment in an open labelled manner. Results: Thirty one of 44 patients experienced relief during capsaicin Treatment periods and did not respond to menthol; all patients not responding to capsaicin also failed on menthol (p<0.0001). In 13 patients, Treatment with capsaicin was unsuccessful: eight patients did not respond to capsaicin Treatment, one responded equally to capsaicin and placebo, and four others dropped out because of side effects. During the follow up period (mean 10.9 (SD 5.8) months), 29 “responders” needed a mean application of capsaicin every day (1.6 (SD 1.2); range 0.5–7 days) to remain symptom free (or nearly symptom free). Conclusion: Capsaicin is a new, safe, and highly Effective Treatment for severe intractable idiopathic pruritus ani.
-
topical capsaicin is a novel and Effective Treatment for idiopathic intractable pruritus ani a randomized placebo controlled study
Gastroenterology, 2001Co-Authors: Joseph Lysy, Mima Sistieriittah, Yardena Israelit, Avigail Shmueli, Eran GoldinAbstract:Background: Pruritus ani is a common and embarrassing proctologic condition. The symptoms of idiopathic pruritus ani can be persistent and severe, and very difficult to treat. Capeaicin depletes Substance P from the peripheral neurons and is known to be Effective in the Treatment of pain, as well as of several itching cutaneous disorders, probable acting through this effect. Methods: A double-blind and placebo controlled study of topical capsaicin in the Treatment of idiopathic, intractable pruritus ani was carried out. Study Design: first, a pilot, open study was done on five patients to establish the best drug concentration. Secondly, 20 patients were randomized to receive locally either active(cepsaicin 0.006%) or placebo (white paraffin) ointement over a two month period. After the two months, the placebo group began to receive capssicin for two months, while the treated group continue the capeaicin t r e ~ only when symptoms recurred. Results: after the first two months, B patients in the treated group (80%) and none in the placebo group, were symptom free (p =0.005) Seven out of ten patients in the placebo group became symptom free when subsequently treated with capeain. Three patients dropped out because of perineal burning due to capeaicin, one in each Treatment group and one in the pilot study group. During the four month follow up, "respooder" patients needed a mean single application of capseicin every four days to remain free of symptoms. Conclusions:Capsaicin is a new, safe and highly Effective Treatment for severe, inetractable idiopathic pruritus ani. Substance P probably plays a key role as a mediator in pruritus ani.
Joseph Lysy - One of the best experts on this subject based on the ideXlab platform.
-
topical capsaicin a novel and Effective Treatment for idiopathic intractable pruritus ani a randomised placebo controlled crossover study
Gut, 2003Co-Authors: Joseph Lysy, D Keret, Yardena Israelit, Avigail Shmueli, M Sistieryittah, N Straussliviatan, Victoria Mindrul, Eran GoldinAbstract:Purpose: Pruritus ani is a common and embarrassing proctological condition which can be very difficult to treat. We report the results of a double blind placebo controlled study of Treatment with capsaicin. Methods: Firstly, a pilot open study was carried out on five patients to establish which of two doses was the most acceptable by comparing Effectiveness and side effects. Secondly, a double blind, placebo controlled, crossover study of topical capsaicin was performed. This study involved two four week Treatment phases separated by a one week washout phase. Forty four patients were randomised to receive locally either active capsaicin (0.006%) or placebo (menthol 1%) ointment over a four week period (22 patients per group). After four weeks of Treatment and a one week washout period, the placebo group began to receive capsaicin while the treated group received placebo (menthol 1%) for another four weeks. At the end of the controlled study, responders from both groups continued with capsaicin Treatment in an open labelled manner. Results: Thirty one of 44 patients experienced relief during capsaicin Treatment periods and did not respond to menthol; all patients not responding to capsaicin also failed on menthol (p<0.0001). In 13 patients, Treatment with capsaicin was unsuccessful: eight patients did not respond to capsaicin Treatment, one responded equally to capsaicin and placebo, and four others dropped out because of side effects. During the follow up period (mean 10.9 (SD 5.8) months), 29 “responders” needed a mean application of capsaicin every day (1.6 (SD 1.2); range 0.5–7 days) to remain symptom free (or nearly symptom free). Conclusion: Capsaicin is a new, safe, and highly Effective Treatment for severe intractable idiopathic pruritus ani.
-
topical capsaicin is a novel and Effective Treatment for idiopathic intractable pruritus ani a randomized placebo controlled study
Gastroenterology, 2001Co-Authors: Joseph Lysy, Mima Sistieriittah, Yardena Israelit, Avigail Shmueli, Eran GoldinAbstract:Background: Pruritus ani is a common and embarrassing proctologic condition. The symptoms of idiopathic pruritus ani can be persistent and severe, and very difficult to treat. Capeaicin depletes Substance P from the peripheral neurons and is known to be Effective in the Treatment of pain, as well as of several itching cutaneous disorders, probable acting through this effect. Methods: A double-blind and placebo controlled study of topical capsaicin in the Treatment of idiopathic, intractable pruritus ani was carried out. Study Design: first, a pilot, open study was done on five patients to establish the best drug concentration. Secondly, 20 patients were randomized to receive locally either active(cepsaicin 0.006%) or placebo (white paraffin) ointement over a two month period. After the two months, the placebo group began to receive capssicin for two months, while the treated group continue the capeaicin t r e ~ only when symptoms recurred. Results: after the first two months, B patients in the treated group (80%) and none in the placebo group, were symptom free (p =0.005) Seven out of ten patients in the placebo group became symptom free when subsequently treated with capeain. Three patients dropped out because of perineal burning due to capeaicin, one in each Treatment group and one in the pilot study group. During the four month follow up, "respooder" patients needed a mean single application of capseicin every four days to remain free of symptoms. Conclusions:Capsaicin is a new, safe and highly Effective Treatment for severe, inetractable idiopathic pruritus ani. Substance P probably plays a key role as a mediator in pruritus ani.
Shinsaku Imashuku - One of the best experts on this subject based on the ideXlab platform.
-
differential diagnosis of hemophagocytic syndrome underlying disorders and selection of the most Effective Treatment
International Journal of Hematology, 1997Co-Authors: Shinsaku ImashukuAbstract:Hemophagocytic syndrome consists of primary and secondary HLH. Efficacy of therapeutic measures and prognosis depend on degree of hypercytokinemia-associated organ failure at disease onset and underlying disorders. The underlying diseases related to hemophagocytosis and informative markers useful for differential diagnoses to select the most Effective Treatment are discussed. Differential diagnosis is difficult between confirmed FEL and familiality-unknown infantile VAHS (or sporadic FEL cases) in primary HLH and also among IAHS, benign EB-VAHS and EBV-related LAHS in secondary HLH. For primary HLH, assay of NK activity and for secondary HLH, studies on the serum cytokine pattern, EBV genomes and clonality determination might prove useful.
-
differential diagnosis of hemophagocytic syndrome underlying disorders and selection of the most Effective Treatment
International Journal of Hematology, 1997Co-Authors: Shinsaku ImashukuAbstract:Copyright (c) 1997 Elsevier Science Ireland Ltd. All rights reserved. Hemophagocytic syndrome consists of primary and secondary HLH. Efficacy of therapeutic measures and prognosis depend on degree of hypercytokinemia-associated organ failure at disease onset and underlying disorders. The underlying diseases related to hemophagocytosis and informative markers useful for differential diagnoses to select the most Effective Treatment are discussed. Differential diagnosis is difficult between confirmed FEL and familiality-unknown infantile VAHS (or sporadic FEL cases) in primary HLH and also among IAHS, benign EB-VAHS and EBV-related LAHS in secondary HLH. For primary HLH, assay of NK activity and for secondary HLH, studies on the serum cytokine pattern, EBV genomes and clonality determination might prove useful. © 1997 Elsevier Science Ireland Ltd.
I Dragojevic - One of the best experts on this subject based on the ideXlab platform.
-
evaluation of Effective Treatment depth in skin cancer Treatments with electronic brachytherapy
Brachytherapy, 2018Co-Authors: Samantha A M Lloyd, Douglas A Rahn, J Hoisak, I DragojevicAbstract:Abstract Purpose To evaluate changes in the percent depth dose (PDD) and Effective depth of Treatment due to force applied by the applicator during Treatments of nonmelanoma skin cancer with the Xoft electronic brachytherapy system. Methods To simulate compressible tissue, a 5-mm tissue-equivalent bolus was used. A soft x-ray ion chamber was used for output measurements, which were performed for all Xoft surface applicators with plastic endcaps in place. Output was first measured at 5 mm depth with minimal pressure from the applicator on the bolus and then repeated after applying uniform pressure on the applicator to calculate the change in PDD and Effective Treatment depth. Results For the 10-mm cone, a moderate force of 5 N changed the PDD by more than 20%. The effect was also pronounced for the 20-mm cone, while minimal for the 35- and 50-mm cones. Even when only a moderate force was applied, the Effective prescription depth changed by several millimeters, on the order of a typical prescription depth. Conclusion Based on the results of this simulation, excessive pressure applied on the skin by the applicator can drastically alter the PDD and Effective Treatment depth. The effect is most pronounced for the 10- and 20-mm cones, which tend to be used most frequently. Inappropriate applicator placement may therefore result in significant consequences such as excessive dose to the target, severe skin reaction, permanent discoloration, skin indentation, and poor overall cosmesis upon completion of Treatment.
-
su e t 387 evaluation of Effective Treatment depth in skin cancer Treatments with xoft electronic brachytherapy
Medical Physics, 2015Co-Authors: I Dragojevic, J HoisakAbstract:Purpose: To evaluate changes in the percent depth dose (PDD) and Effective depth of Treatment based on exerted force by applicator on the skin during Treatments of skin cancer with Xoft Electronic Brachytherapy. Methods: To simulate compressible tissue, 5mm tissue-equivalent bolus was used. An ion chamber (Soft X-ray Chamber, PTW) and electrometer (Max 4000, Standard Imaging) were used for output measurements. Measurements were done for all available Xoft surface applicators (10, 20, 35, and 50mm cones) with plastic endcap. Fig1 shows the experimental setup. The PDD was measured first with no or minimal pressure of the applicator on the bolus, followed by increasing uniform pressure on the applicator applied with custom cerrobend weights. The measurements were used to calculate the Effective PDD and Effective depth. Results: Force applied with the applicator was plotted against the change in PDD relative to the PDD when no force is applied. For the 10mm cone, moderate force of 5N can change the PDD by more than 20%, (Fig2). The effect is also pronounced for the 20mm cone, while it is minimal for the 35 and 50mm cones. Even when only moderate force is applied, the Effective prescription depth can be changed by a several millimeters, which is on the order of the typical prescription depth (Fig3). Conclusion: Based on the results of this simulation, excessive pressure applied on the patient’s skin by the applicator cone can drastically alter the PDD and Effective Treatment depth. The effect is most pronounced for the 10mm cone, and to a lesser extent, 20mm, which is significant as these cones tend to be used most frequently in the clinic. Applicator placement therefore may Result in significant consequences such as excessive dose to target, severe skin reaction, permanent discoloration, skin indentation, and poor overall cosmesis upon completion of Treatment.
Yardena Israelit - One of the best experts on this subject based on the ideXlab platform.
-
topical capsaicin a novel and Effective Treatment for idiopathic intractable pruritus ani a randomised placebo controlled crossover study
Gut, 2003Co-Authors: Joseph Lysy, D Keret, Yardena Israelit, Avigail Shmueli, M Sistieryittah, N Straussliviatan, Victoria Mindrul, Eran GoldinAbstract:Purpose: Pruritus ani is a common and embarrassing proctological condition which can be very difficult to treat. We report the results of a double blind placebo controlled study of Treatment with capsaicin. Methods: Firstly, a pilot open study was carried out on five patients to establish which of two doses was the most acceptable by comparing Effectiveness and side effects. Secondly, a double blind, placebo controlled, crossover study of topical capsaicin was performed. This study involved two four week Treatment phases separated by a one week washout phase. Forty four patients were randomised to receive locally either active capsaicin (0.006%) or placebo (menthol 1%) ointment over a four week period (22 patients per group). After four weeks of Treatment and a one week washout period, the placebo group began to receive capsaicin while the treated group received placebo (menthol 1%) for another four weeks. At the end of the controlled study, responders from both groups continued with capsaicin Treatment in an open labelled manner. Results: Thirty one of 44 patients experienced relief during capsaicin Treatment periods and did not respond to menthol; all patients not responding to capsaicin also failed on menthol (p<0.0001). In 13 patients, Treatment with capsaicin was unsuccessful: eight patients did not respond to capsaicin Treatment, one responded equally to capsaicin and placebo, and four others dropped out because of side effects. During the follow up period (mean 10.9 (SD 5.8) months), 29 “responders” needed a mean application of capsaicin every day (1.6 (SD 1.2); range 0.5–7 days) to remain symptom free (or nearly symptom free). Conclusion: Capsaicin is a new, safe, and highly Effective Treatment for severe intractable idiopathic pruritus ani.
-
topical capsaicin is a novel and Effective Treatment for idiopathic intractable pruritus ani a randomized placebo controlled study
Gastroenterology, 2001Co-Authors: Joseph Lysy, Mima Sistieriittah, Yardena Israelit, Avigail Shmueli, Eran GoldinAbstract:Background: Pruritus ani is a common and embarrassing proctologic condition. The symptoms of idiopathic pruritus ani can be persistent and severe, and very difficult to treat. Capeaicin depletes Substance P from the peripheral neurons and is known to be Effective in the Treatment of pain, as well as of several itching cutaneous disorders, probable acting through this effect. Methods: A double-blind and placebo controlled study of topical capsaicin in the Treatment of idiopathic, intractable pruritus ani was carried out. Study Design: first, a pilot, open study was done on five patients to establish the best drug concentration. Secondly, 20 patients were randomized to receive locally either active(cepsaicin 0.006%) or placebo (white paraffin) ointement over a two month period. After the two months, the placebo group began to receive capssicin for two months, while the treated group continue the capeaicin t r e ~ only when symptoms recurred. Results: after the first two months, B patients in the treated group (80%) and none in the placebo group, were symptom free (p =0.005) Seven out of ten patients in the placebo group became symptom free when subsequently treated with capeain. Three patients dropped out because of perineal burning due to capeaicin, one in each Treatment group and one in the pilot study group. During the four month follow up, "respooder" patients needed a mean single application of capseicin every four days to remain free of symptoms. Conclusions:Capsaicin is a new, safe and highly Effective Treatment for severe, inetractable idiopathic pruritus ani. Substance P probably plays a key role as a mediator in pruritus ani.
